e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.
Y. Kida (Kobe, Japan), A. Ikeda (Kobe, Japan), T. Ninomaru (Akashi, Japan), H. Ohnishi (Akashi, Japan), N. Katakami (Kobe, Japan)
Source:
International Congress 2019 – Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Poster Discussion
Number:
378
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Kida (Kobe, Japan), A. Ikeda (Kobe, Japan), T. Ninomaru (Akashi, Japan), H. Ohnishi (Akashi, Japan), N. Katakami (Kobe, Japan). Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.. 378
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC).
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 753s
Year: 2006
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients
Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Year: 2012
Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept